Latest
The day's market news, with the argument attached
New notes every trading day on earnings, policy and market structure. Each one opens with the conclusion, then the evidence, then the companies it hits.
2026-07-21
%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%22220%22%20cy%3D%22150%22%20r%3D%22180%22%20fill%3D%22%2322d3ee%22%20fill-opacity%3D%220.12%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%221010%22%20cy%3D%22130%22%20r%3D%22220%22%20fill%3D%22%2338bdf8%22%20fill-opacity%3D%220.08%22%2F%3E%0A%20%20%3Ccircle%20cx%3D%22920%22%20cy%3D%22520%22%20r%3D%22170%22%20fill%3D%22%2322d3ee%22%20fill-opacity%3D%220.06%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M140%20430h920%22%20stroke%3D%22url(%23line)%22%20stroke-width%3D%2212%22%20stroke-linecap%3D%22round%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M220%20360c120-150%20260-220%20380-220s260%2070%20380%20220%22%20fill%3D%22none%22%20stroke%3D%22%2367e8f9%22%20stroke-opacity%3D%220.5%22%20stroke-width%3D%2216%22%20stroke-linecap%3D%22round%22%20stroke-linejoin%3D%22round%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M300%20398h600%22%20stroke%3D%22%2394a3b8%22%20stroke-opacity%3D%220.24%22%20stroke-width%3D%228%22%20stroke-linecap%3D%22round%22%2F%3E%0A%20%20%3Ctext%20x%3D%22220%22%20y%3D%22510%22%20fill%3D%22%23e2e8f0%22%20fill-opacity%3D%220.7%22%20font-family%3D%22Arial%2C%20Helvetica%2C%20sans-serif%22%20font-size%3D%2238%22%20letter-spacing%3D%228%22%3EINSIGHTS%3C%2Ftext%3E%0A%3C%2Fsvg%3E)
14-Day TRO Forces Paramount Skydance to Pause the $110B WBD Deal—The Mega-Media M&A Era’s First Real Court Litmus Test
On July 20, 2026, a U.S. district judge granted a 14-day TRO blocking Paramount Skydance’s $110B acquisition of Warner Bros. Discovery (through at least an Aug. 3 hearing). The order turns what had been “regulatory risk” into an economic squeeze: WBD shares dropped ~3.8% that day and the deal’s structure includes a $0.25-per-share ticking fee if the close slips past Sept. 30. For investors, the core question is whether this is a short delay—or the opening move in a longer antitrust fight over wide-release theatrical distribution and cable power.
Reformation’s IPO Terms Price a “Profitable DTC” Outfitter for Public Markets—But the Margin Story Still Hinges on Tariffs and Scale
Reformation’s ref S-1/A sets a $15.00–$17.00 range for a roughly $225M raise on $507.1M of 2025 revenue and $12.6M net income, with ~90% of sales from direct-to-consumer. The filing’s most investment-relevant detail isn’t the DTC mix—it’s how much reported gross margin and operating leverage swing around tariff-driven costs/refunds and store expansion discipline. If Reformation can convert store growth into steadier margins, the “profitable sustainable DTC” thesis looks investable; if not, the valuation can compress fast even with positive net income.
Scribe Therapeutics’ $100M IPO Is the First Public “Pure-Play CRISPR Risk Read” of 2H 2026—And It’s Valuing Epigenetic Gene Editing Like a Clinical-Stage Bet
Scribe Therapeutics (Scribe Therapeutics) set Nasdaq IPO terms for 7.15M shares at $13–$15, seeking about $100M at the low end and up to $107.2M at the top, with Sanofi participating in a concurrent purchase. The S-1 frames its core value creation around early, in-human data for its lead epigenetic CRISPR program (Scribe Therapeutics STX-1150]) and preclinical progress for two lipid-risk follow-ons funded partly by CIRM grants. For investors, the key question isn’t just CRISPR’s science—it’s whether public markets will underwrite early-stage execution risk after the post-2024/25 biotech window reopened.
Trump Slaps 50% Tariffs on $20B of Canadian Goods Under Section 338 — Markets Brace for New Trade Shock
On July 20, 2026, President Trump signed three proclamations under Section 338 of the Tariff Act of 1930, imposing a 50% tariff on approximately $20 billion of Canadian goods — including motor vehicles, wine, spirits, beer, dairy, cement, lumber, and even hockey sticks — to retaliate against Canadian trade discrimination. The tariffs take effect in 30 days and apply regardless of USMCA status. Energy, potash, fish, Section 232 products, and critical minerals are exempted. Cited drop data: Canadian imports of U.S. vehicles fell ~22% ($5.6B) from April 2025 to March 2026; U.S. alcohol imports to Canada fell ~81% ($582M) from March 2025 to February 2026.
2026-07-20
AliExpress's Record €550M EU DSA Fine: A Watershed for Cross-Border E-Commerce Compliance
On July 20, 2026, the European Commission hit Alibaba-owned AliExpress with a record €550 million ($629M) fine under the Digital Services Act for systemic failures to tackle illegal, counterfeit, and unsafe products on its platform — exceeding the €120M fine on X and the €200M on Temu. The Commission cited inadequate risk staffing, overestimated content-moderation efficacy, weak penalty enforcement against repeat-offender sellers, and a brand-authorization system easily circumvented. AliExpress has 193M European users (vs Shein's 156M, Temu's 130M).
Bezos, Nvidia, Meta Back CuspAI's $450M Series B and 'AI Materials Foundry' — AI Drug-Discovery-Style Bets Now Target Chipmaking Inputs
On July 20, 2026, Cambridge-based CuspAI launched its 'AI Materials Foundry' — a coalition of 45+ technology firms, industrial players, and research labs — alongside a $450 million Series B led by Jeff Bezos with participation from Nvidia (compute), Meta FAIR (Universal Model for Atoms), Kleiner Perkins, NEA, and Temasek, bringing total funding to $650 million. Powered by CuspAI's 'MIRA' platform, the Foundry already screened 300 trillion molecular structures for client Kemira in 6 months (versus years traditionally) and uses curated data from the Cambridge Structural Database, Inorganic Crystal Structure Database, and Wiley. The bet signals that generative-AI-for-materials — analogous to AI drug discovery — is now being explicitly aimed at chipmaking materials bottlenecks.
Databricks' $188B Coatue-Led Round Resets the Private-AI Ceiling: What a 40% Markup in Six Months Says About the Enterprise Data Stack
On July 17, 2026, Databricks signed a term sheet for a strategic funding round led by Coatue that values the data/AI platform at $188B — a roughly 40% step-up from its ~$134B valuation in December 2025. The round totals about $3B from new and existing investors and is expected to close later this summer. It comes on the heels of a separate ~$5B raise earlier in 2026 and stretches Databricks' lead as the most valuable non-foundation-model AI private company, sharpening questions about IPO timing, AI infrastructure economics, and the relative pricing of public SaaS peers.
Domino's Pizza Q2 FY2026 Earnings: $4.07 EPS Beats, but U.S. Same-Store Sales Flatline at 0.1%
Domino's Pizza reported Q2 FY2026 results before the open on July 20, 2026: diluted EPS of $4.07 (vs $3.81 prior year, beat consensus), revenue of $1.194B (+4.3% YoY, beat), but U.S. same-store sales growth of just 0.1% (well below consensus expectations of ~1.5%) and international same-store sales of -0.1%. Global retail sales grew 3.0% excluding FX. The company added 209 net new stores (26 U.S., 183 international).
Goldman Sachs' Three Alternatives to the AI Trade: Consumer Compounders, Quality Compounders, and M&A Targets
On July 19, 2026, Goldman Sachs strategists published a note flagging three investment themes as alternatives to the volatile AI infrastructure trade: (1) consumer experience stocks benefiting from discretionary spending with limited AI disruption risk, (2) high-quality compounders with 15 names identified, and (3) potential M&A targets as U.S. announced deal activity hits $1.2T, up 32% YoY. The note comes as hedge fund positioning in AI infrastructure names has grown crowded and visibility on further AI capex is shrinking.
India's Private Banks Slump 5% as HDFC, Axis, Kotak Q1 FY27 Margins Disappoint
On July 20, 2026, leading Indian private-sector banks fell ~5% intraday after their Q1 FY27 results (reported July 18–19) revealed sharper-than-expected net interest margin compression: HDFC Bank fell 5% (steepest intraday drop in 4 months) on a 13bp sequential NIM decline; Axis Bank dropped 5.03% on soft NII growth; Kotak fell 3.06% despite a 26% YoY net profit rise. ICICI was a relative outperformer. The Nifty Private Bank index was dragged lower; HDFC is down ~20% YTD.
Micron Stock Snap: SK Hynix's Memory Price Warning Reprices the AI Memory Oligopoly
On July 19–20, 2026, Micron shares snapped a recent losing streak after an SK Hynix memory-price warning reinforced that the AI-driven DRAM/HBM cycle remains supply-constrained into 2027 and beyond. The warning follows SK Hynix CEO Kwak Noh-jung's comments on July 10 calling 2027 the 'worst year' for memory supply shortages, with the crunch expected to last to 2030 — and comes as memory stocks (SK Hynix, Micron, SanDisk, Western Digital) sold off sharply the prior week on concerns about peak-cycle pricing.
Molex-Prysmian's $6.29B Data-Center Cable Deal Is the Newest Anchor for the Hyperscaler Optical Supply Chain
On July 20, 2026, Koch-owned Molex struck a 10-year, up to $6.29 billion (€5.5 billion) deal with Italy's Prysmian for the supply of optical cables used inside AI data centers, including a €550 million upfront payment. The agreement — one of the largest hyperscaler-adjacent cabling contracts ever disclosed — follows Prysmian's May 2026 guidance that hyperscaler deals would push 2028 EBITDA up ~64% from 2024, and a $4.68B M&A exploration to bolt on capacity. The deal locks in critical optical interconnect supply at a moment when AI-driven data-center fiber demand is competing with telecom and subsea projects for the same Prysmian capacity.
Prologis's Third $18.2B Bid for Segro Just Got Rejected — What Happens Before the July 22 Takeover Panel Deadline
On July 17, 2026, Segro's board unanimously rejected Prologis's third sweetened takeover offer valued at approximately £13.5 billion ($18.16 billion), comprising £2.7 billion in cash and 0.0890 new Prologis shares per Segro share. The bid carries a 33.8% premium to Segro's June 23 closing price but was dismissed as still materially undervaluing the UK warehouse landlord. Under UK Takeover Panel rules, Prologis has until July 22, 2026 to either make a formal offer or walk away, with Bloomberg reporting a possible secondary London Stock Exchange listing as a sweetener. The proposed merger would create the world's largest industrial REIT at a time when data-center demand is reshaping the logistics property thesis.
Samsung Biologics $1.8B All-Cash Bid for PolyPeptide: Korea's Biggest CDMO Bet Yet on the GLP-1 Peptide Boom
On July 19-20, 2026, Samsung Biologics launched an all-cash public tender offer to acquire 100% of Swiss API peptide manufacturer PolyPeptide Group at CHF 44.31 per share, valuing the deal at approximately CHF 1.46 billion (~$1.8B) and marking the largest overseas acquisition by a Korean CDMO. The offer carries a 40% premium to the undisturbed April 10 price and an 11.6% premium to the 60-day VWAP, and is backed by an irrevocable tender undertaking from PolyPeptide's largest shareholder representing ~55.65% of shares. Strategically, the deal gives Samsung Biologics a multi-modality platform with six GMP facilities across Europe, the US and India and direct exposure to GLP-1 peptide manufacturing, competing with Novo Holdings' $16.5B Catalent acquisition and CordenPharma's ~$1B peptide CDMO push.
Shein Clears Hong Kong Listing Committee at $40-50B: Fast Fashion's Biggest 2026 IPO Pivots East After the NY/London Fades
On July 17, 2026, Shein received approval from the Hong Kong Stock Exchange listing committee for its long-awaited IPO, targeting a $40-50B valuation (down from $100B in 2022). The fast-fashion retailer plans to publish its first public filing the week of July 27 and could launch the roadshow as soon as late August, after pivoting away from prior New York and London attempts. The prospectus will offer a clean read on Shein's $40B+ revenue, ~$2B net profit, supply chain, and the regulatory tradeoffs of choosing Hong Kong over U.S. listings.
TSMC Accelerates Arizona Buildout, Lifts 2026 Capex to $60-64B — The AI 'Megatrend' Is Now a US Foundry Story
On July 20, 2026, TSMC CFO Wendell Huang told CNBC the company is accelerating its Arizona fab buildout to capitalize on what he called a 'multi-year structural' AI 'megatrend', with the Arizona pipeline raised to $265 billion on top of an additional $100 billion commitment. TSMC simultaneously lifted full-year 2026 capex guidance to $60-64 billion (from a prior $52-56B) and confirmed Phase 1 of Arizona is in production on 4nm, with advanced packaging also being built on-site. Crucially, Huang disclosed that US fab construction costs run 4-5x Taiwan levels, a key margin datapoint for assessing the long-run economics of US-based AI chip manufacturing.
2026-07-19
The AI Selloff Is Repricing Duration, Not Demand, as Oil and Rates Hit the Tape
A one-day drop in AI stocks is not a demand collapse story. The tape is telling investors that the most crowded parts of the AI complex are now being judged like long-duration assets, while oil, rates, and leverage force the market to separate Nvidia from Micron, SK Hynix, and Samsung Electronics.
American Airlines’ $3 Billion Profit Gap: Turnaround Plan Meets a Structural Revenue Problem
American Airlines is trying to close a wide peer profit gap through premium cabins, lounges, schedule redesign, loyalty monetization, and fleet investment. The starting point is stark: revenue is only modestly below United's, but net income is far lower, which points to a structural monetization and cost-of-capital problem rather than a simple scale issue.
The Beige Book Says Growth Is Still Moderate, but Fuel and Tariffs Keep the Fed on Guard
The latest Beige Book says the U.S. economy is still expanding at a moderate pace, but higher fuel costs and tariff pressure mean the Fed cannot treat inflation as solved. That keeps Walmart, United Airlines, and rate-sensitive sectors tied to the next policy print.
CFM's $2 Billion Repair Plan Says Aviation's Bottleneck Is Aftermarket Capacity, Not Engine Demand
CFM's five-year, $2 billion repair push is a signal that the supply problem in commercial aviation sits in maintenance, parts, and turn time. That has direct read-through for GE Aerospace, Safran, Boeing, and the airlines that are paying for missed utilization.
What to expect
Evidence-first notes with a visible point of view.
This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.
Expect direct analysis, not generic commentary.
Expect the data to be explicit and the argument to be easy to follow.
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer